Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or
disappointment this will cause

8:25 am Chair’s Opening Remarks

  • Uli Schmitz Executive Director Structural Biology and Chemistry, Gilead Sciences

Learning From the Successes & Failures of Recent Practical Use Cases to Successfully Implement & Utilize Machine Learning in R&D Processes

8:30 am End-to-End ML Approach to Identify Subphenotypes & Trajectories in Heterogeneous Diseases


  • Exploring heterogeneous diseases to identify meaningful phenotypes to aid drug discovery
  • Using this approach on ARDS to enable the identification of meaningful subphenotypes with high accuracy
  • The combination of curating high-quality datasets and using sophisticated ML opens the possibility of scaling the approach to other heterogeneous diseases

9:00 am Roundtable Discussion: Avoiding an AI Winter: Delineating the Approach Towards Responsible Auditing at a Data, Modelling & Inference Level to Maximize Responsible & Effective Use


  • What operational standards and regulatory procedures need to be put in place to move forward?
  • Uniting as a community to establish a clear AI strategy
  • Reducing the number of failures by overcoming the data paucity problem

This session is your opportunity to share your most pressing challenges, and work in small groups to come up with solutions you can implement right away! Each topic area will have several small groups, and each group will have 20 minutes to discuss ways to avoid an AI winter. Groups will then share their findings with all attendees, giving you maximum exposure to new ideas! 

Utilising the Power of AI to Identify & Validate Novel Targets to Accelerate Early Drug Discovery Efforts

9:30 am Entering a New Era of Target Identification & Lead Optimization Using a Structure-Based Generative Chemistry Approach to Treat Hepatocellular Carcinoma

  • Petrina Kamya Global Head of AI Platforms, VP Insilico Medicine; President, Insilico Medicine Canada, Insilco Medicine Canada


  • Highlighting the strengths and weaknesses in leveraging AI for target identification
  • How has AI been used to make molecules more selective and efficient?
  • Revealing CDK20 cell-based data and the time saved by using AI

10:00 am Speed Networking


This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the AI/ML field and establish meaningful business relationships

10:30 am Morning Break & Networking

11:00 am Discovering New Leads by in silico Screening Millions of Compounds Against Target Activity Models of Different Types

  • Ruben Abagyan Professor, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California


  • Defining exact multiple target and pocket profile based on the genomics analysis of treatment resistant patients
  • Identifying druggable pockets in new targets, transient states, and hidden or allosteric pockets for higher selectivity
  • Screening giga-catalogs of compounds to find leads in oncology, neurology, and viral diseases

11:30 am Identifying Novel Targets & Combinations by Leveraging Results From Preclinical Screening of Drug Sensitivity in Molecular Cell Lines

  • Jadwiga Bienkowska Senior Director & Head of Computational Biology & Oncology Research, Pfizer


  • Developing ML models to predict a response to novel drug therapies in cell lines
  • Effectively translating models to predict patients’ responses in clinical and real-world data
  • Positioning the next generation therapy to best leverage the novel therapies’ potential

12:00 pm Panel Discussion: Assessing the Failures in Target Identification to Navigate the Route Towards Success

  • Petrina Kamya Global Head of AI Platforms, VP Insilico Medicine; President, Insilico Medicine Canada, Insilco Medicine Canada
  • Ruben Abagyan Professor, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California
  • Jadwiga Bienkowska Senior Director & Head of Computational Biology & Oncology Research, Pfizer


  • Leveraging new methods and multiple models to cope with the sheer number of possible molecules
  • Addressing the scepticism: How novel are targets for small molecules and antibodies?
  • Identifying appropriate context experts and infrastructure and scaling requirements for different data modalities

12:30 pm Lunch Break & Networking

Drugging the Targets: Unravelling Predictive Models for Drug Synthesis & Yield Optimization

1:30 pm Unravelling Novel Generative Design of Peptide Therapeutics & Elucidating Their Safety


  • Reiterating the value of small peptides as nontoxic and stable drugs
  • Unveiling the use of generative AI for the development of cell penetrating peptides for a broad range of diseases
  • Demonstrating concrete examples of the cons and gains of utilising this technology to discover novel and specific protein-protein interactions

Accelerating Preclinical Development With AI-Predicted Outcomes & Automating Drug Design Workflows With AI

2:00 pm Developing Spatial Analytic Tools for Characterising the Tumour Microenvironment

  • Arvind Rao Associate Professor, Computational Medicine & Bioinformatics, Radiation Oncology, University of Michigan


  • Discussing the notion of discovering spatial biomarkers for immunotherapy
  • Illuminating the need for analytical platforms to interpret specific kinds of data sets
  • Elucidating the effective translation for clinical decision making

2:30 pm Compound Activity Prediction with Dose-Dependent Transcriptomic Profiles & Transformer Models


  • Leveraging gene-expression profiles to predict activity in biochemical and cellular assays
  • Using Transformer models with sequence of transcriptomes from compound treatment over multiple concentrations as input
  • Activity predictions validate experimentally, even when transcriptomes are measured in human but activity predicted and tested in Plasmodium parasites

3:00 pm Afternoon Break & Poster Session


This Poster Session is your go-to session to obtain competitive insights, deeply connect with your peers and present your most innovative work. Scientific posters will be presented on the most cutting-edge AI-driven discovery and preclinical efforts that have the potential to drive the field forward.

For more information or to submit your abstract, please email info@hansonwade.com

3:30 pm Spotlighting New Sources for Personalized Neoantigen Treatment


  • Overcoming the difficulties found in patients with low number of mutations by exploring  novel personalized cancer treatments that aren’t solely targeting neoepitopes arising from missense mutations
  • Discovering new sources of targetable epitopes to develop personalized cancer vaccines in patient populations with low mutational burden (low-TMB)
  • Exploring genomic rearrangement, splice variants and ERVs as potential new sources to be utilized in tomorrows’ personalised cancer vaccines

4:00 pm Novel Insights into Computational T Cell Epitope Removal

  • Yifan Song Chief Science Officer, Cyrus Biotechnology Inc.


  • How to interpret and incorporate experimental data into computational design algorithms
  • Development of algorithms for deimmunization
  • Discussion of validation assays

4:30 pm Chair’s Closing Remarks